RFA-AR-25-014: Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2025.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 9, 2025.
From the official notice on Grants.gov, last changed December 9, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUH3
- Clinical trialsOptional
- Funded byNHLBI, NEI
- Median yearly award$1.0 million
- Typical project length5 years
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-AR-25-014 were run by National Heart Lung and Blood Institute (NHLBI, 1 project) and National Eye Institute (NEI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AR-25-014 in the NIH Guide.
Key dates
| Posted | June 17, 2025 |
|---|---|
| Deadline | December 9, 2025 |
| Archived by Grants.gov | February 7, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 5 programs behind this notice (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Required)
Funded under RFA-AR-25-014 so far
NIH funded 2 projects under RFA-AR-25-014 in fiscal 2026, at 2 institutions. The median yearly award was $1.0 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2) | Research Inst Nationwide Children's Hosp | 2026 | $974,238 |
| Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | Regenerative Research Foundation | 2026 | $1.1 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Vision Research grants before
From fiscal 2021 to 2025, Vision Research (93.867) awarded $3.4 billion across 3,275 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 137 | $139 million |
| The Leland Stanford Junior University | California | 87 | $96.5 million |
| The Regents of the University of California, San Francisco | California | 78 | $89.9 million |
| Duke University | North Carolina | 79 | $75.5 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 57 | $73.9 million |
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before
From fiscal 2021 to 2025, Arthritis, Musculoskeletal and Skin Diseases Research (93.846) awarded $2.6 billion across 2,897 grant awards, an average of $908,766 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 104 | $104 million |
| Brigham & Womens Hospital Inc | Massachusetts | 89 | $95.7 million |
| The Regents of the University of California, San Francisco | California | 84 | $93.3 million |
| The Washington University | Missouri | 88 | $72.4 million |
| Regents of the University of Michigan | Michigan | 73 | $68.0 million |
Other programs behind this notice
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AR-25-014 still open?
No. It closed on December 9, 2025.
Who can apply for Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)?
Closed December 9, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AR-25-014?
NIH RePORTER lists 2 projects funded under RFA-AR-25-014 in fiscal 2026, at 2 institutions. The most were at Research Inst Nationwide Children's Hosp, Regenerative Research Foundation.
Who has won Cardiovascular Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)